Business Context and Reporting Period
This Form 8-K Current Report was filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on October 12, 2017, with the earliest event reported on October 13, 2017. The filing details the entry into a Material Definitive Agreement regarding a registered direct offering of securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $8 million from the sale of 3,265,309 shares of common stock and warrants exercisable for up to 1,632,654 shares.
- Offering Price: $2.45 per unit (one share plus a warrant for 0.5 share).
- Net Proceeds: Approximately $7.4 million after deducting fees and expenses.
- Placement Agent Fees: Up to 6% of gross proceeds plus $30,000 in non-accountable expenses paid to H.C. Wainwright & Co., LLC.
- Warrant Terms: Investor warrants have an exercise price of $2.85 per share; Agent warrants (195,919 shares) have an exercise price of $3.06 per share.
- Liquidity and Debt: The filing text does not provide current liquidity ratios, total debt levels, or cash flow statements.
Material Changes and Transaction Structure
The primary material change is the execution of securities purchase agreements to raise capital. The offering structure involves selling units consisting of common stock and warrants. The warrants are exercisable beginning six months after issuance and expire five years from the initial exercise date. The transaction is expected to close on or about October 17, 2017, subject to customary closing conditions.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future operational performance. The primary risk noted is the dilution of existing shareholders due to the issuance of new shares and warrants. The closing of the transaction is contingent upon the satisfaction of customary conditions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected October 17, 2017).
- Confirm the exact number of shares issued and the final net proceeds received after all expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Monitor the company's cash position post-closing to assess runway for operations.
- Check for any subsequent filings regarding the exercise of warrants or changes in the capital structure.